1-9 A-D E-G H-M N-P Q-S T-Z

SODYUM PERİYODAT (SODIUM PERIODATE)

Sodium Periodate
Synonyms: Sodium Periodate; sodiumperiodate; sodyum periodat; sodyum periyodat; Sodyum Periyodat; Sodyum Periyodat; sodyum peryodat; SODYUM PERYODAT; SodyumPeriodat; sodiummetaperiodate; Sodyumat; Sodium Metaodat; periodatesodium; periyodatsodyum; Periodate Sodium; Periyodat Sodyum; Periodat Sodyum; periodatsodyum; periyodat; periodat; SODYUM; Periodate; Meta Periodate Sodıum; Meta Periyodat Sodyum; sometaperiodate; NaIO4; compound periodate; periodate ion; sodium metaperiodate; sodium periodate; Sodium periodate; 7790-28-5; Sodium metaperiodate; Sodium m-periodate; sodiumperiodate;sodium meta-periodate; Sodium (meta)periodate; Periodic acid; sodium salt; Periodic acid (HIO4); sodyum salt; Sodium meta periodate; UNII-98W4A29X43; HSDB 7298; EINECS 232-197-6; MFCD00003534; Periodate sodium; Periodic acid (HIO4); sodium salt (1:1); 98W4A29X43; Sodium periodate 99%; Sodium periodate, 99; SODYUM PERYODAT %99 ACS reagent; sodium penodate; sodium periodat; sodium-m-periodate; sodium(meta)periodat; sodium-meta-periodate; INaO4; NaIO4; PubChem21354; sodium (meta) periodate; AC1Q1VAV; ACMC-1C1BE; EC 232-197-6; AC1Q22GV; Sodium periodate; ACS grade; SODIUM PERIODATE, ACS; KSC492E4T; ARONIS24207; Lithium Chelate 0.2%, 40M; CHEBI:75226; CTK3J2249; DTXSID30894075; JQWHASGSAFIOCM-UHFFFAOYSA-M; BCP04945; KS-00000X4M; ZX-AS004562; ANW-37125; AKOS005267138; AKOS015950617; RP26776; RTC-064027; TRA0082821; BP-21195; R917; SC-15186; AB1002303; LS-102438; TC-064027; FT-0689066; C-58503; I14-16479 IONAM; metaperiodate; Sodium periodate; Periodate sodium; SODIUM M-PERIODATE; sodiummetaperidate; Sodium metapriodate; SODIUM METAPERIODATE; SODIUM PERIODATE META; SodiumMetaperiodateGr; odium Periodate; sodiumperiodate; sodyum periodat; sodyum periyodat; Sodyum Periyodat; Sodyum Periyodat; sodyum peryodat; SODYUM PERYODAT; SodyumPeriodat; sodiummetaperiodate; Sodyumat; Sodium Metaodat; periodatesodium; periyodatsodyum; Periodate Sodium; Periyodat Sodyum; Periodat Sodyum; periodatsodyum; periyodat; periodat; SODYUM; Periodate; Meta Periodate Sodıum; Meta Periyodat Sodyum; sometaperiodate; NaIO4; compound periodate; periodate ion; sodium metaperiodate; sodium periodate; Sodium periodate; Sodium metaperiodate; Sodium m-periodate; sodiumperiodate;sodium meta-periodate; Sodium (meta)periodate; Periodic acid; sodium salt; Periodic acid (HIO4); sodyum salt; Sodium meta periodate; UNII-98W4A29X43; HSDB 7298; EINECS; MFCD00003534; Periodate sodium; Periodic acid (HIO4); sodium salt 1:1; Sodium periodate %99; Sodium periodate, 99; ACS reagent; sodium penodate; sodium periodat; sodium-m-periodate; sodium(meta)periodat; sodium-meta-periodate; INaO4; NaIO4; Sodium periodate ACS grade; SODIUM PERIODATE ACS; LITHIUM CHELATE; metaperiodate; Sodium periodate; Periodate sodium; SODIUM M-PERIODATE; sodiummetaperidate; Sodium metapriodate; SODIUM METAPERIODATE; SODIUM PERIODATE META;

Sodium periodate
ACS reagent, ≥99.8%
CAS Number 7790-28-5 Linear Formula NaIO4 Molecular Weight 213.89 EC Number 232-197-6 MDL number MFCD00003534 PubChem Substance ID 329753668Properties
Related Categories Chemical Synthesis, Detection of Biotin Labeled Glycoproteins on Western Blots, Essential Chemicals, Glycobiology, Glycoprotein Detection,
grade ACS reagent
InChI Key JQWHASGSAFIOCM-UHFFFAOYSA-M
assay ≥99.8%
99.8-100.3% dry basis (ACS specification)
impurities ≤0.02% other halogens (as Cl)
mp 300 °C (dec.) (lit.)
cation traces Mn: ≤3 ppmApplication
Generates quinones via glycol cleavage and oxidation of hydroquinones Sodium periodate is an inorganic sodium salt having periodate as the counterion. It has a role as an oxidising agent. It contains a periodate.Conformer generation is disallowed since MMFF94s unsupported element, MMFF94s unsupported atom valence, mixture or salt.Molecular Weight 213.892 g/mol Computed by PubChem 2.1 (PubChem release 2019.06.18)
Hydrogen Bond Donor Count 0 Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Hydrogen Bond Acceptor Count 4 Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Rotatable Bond Count 0 Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Exact Mass 213.8739 g/mol Computed by PubChem 2.1 (PubChem release 2019.06.18)
Monoisotopic Mass 213.8739 g/mol Computed by PubChem 2.1 (PubChem release 2019.06.18)
Topological Polar Surface Area 74.3 Ų Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Heavy Atom Count 6 Computed by PubChem
Formal Charge 0 Computed by PubChem
Complexity 118 Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Isotope Atom Count 0 Computed by PubChem
Defined Atom Stereocenter Count 0 Computed by PubChem
Undefined Atom Stereocenter Count 0 Computed by PubChem
Defined Bond Stereocenter Count 0 Computed by PubChem
Undefined Bond Stereocenter Count 0 Computed by PubChem
Covalently-Bonded Unit Count 2 Computed by PubChem
Compound Is Canonicalized Yes Computed by PubChem (release 2019.01.04). White, tetragonal crystals.Decomposes approx 300 °C.Soluble in cold water, sulfuric, nitric, acetic acids

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1543
from HSDB.When heated to decomposition it emit toxic fumes of /hydrogen iodide and sodium oxide/.White, efflorescent, trigonal crystals; density 3.219 at 18 °C; decomposes at 175 °C; 1 gm dissolves in 8 ml water at 20 °C /Trihydrate/
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1543. In a pilot study involving 13 patients with advanced stage IV renal cell carcinoma, anti-tumor effects and toxicity of a novel form of adoptive immunotherapy were determined. The protocol utilizes infusions of autologous mononuclear leukocytes treated with the oxidizing mitogen sodium periodate (IO4-) and cultured in medium containing human recombinant interleukin-2 (IL-2), and continuous infusions of low-dose IL-2 (mean +/- SD dose = 39.5 +/- 8.6 X 10(3) U/kg/24 hours). Leukocytes (5 to 10 X 10(9)) were removed by leukapheresis three times per week, mononuclear cells were separated, activated with IO4- and cultured in medium containing IL-2 (500 U/ml) for 48 to 72 hours. The cells were re-infused following the next leukapheresis procedure. IL-2 was administered five days per week. Treatment was continued for two three-week cycles. An increase in peripheral blood mononuclear cells bearing the natural killer cell (NK) surface marker, Leu 11, an increase in NK- and antibody-dependent cell-mediated cytotoxicity, and a slight increase in spontaneous cytotoxicity for non-NK targets were noted. Regressions (more than 50 percent decrease in tumor mass) of pulmonary, liver, bone, or soft tissue metastases were induced in six patients. Severe fluid retention did not develop in any patient and no patient required treatment in the intensive care unit. Five of the patients who showed a response have experienced a relapse at 5.2 +/- 1.0 (mean +/- SD) months. These observations indicate that IO4-/IL-2-activated killer cells plus continuous infusions of low-dose IL-2 can result in regression of metastatic renal cell carcinoma. /Exptl Ther/

PMID:2845776
Wang J et al; Am J Med 83 (6): 1016-23 (1987). the results of a pilot study that determined the effects of both intermittent injections of periodate and recombinant interleukin-2 (rIL-2)-activated leukocytes and continuous infusions of low doses of rIL-2 on metastases of nine patients with stage IV renal cancer /are reported/. Four patients experienced regressions, two patients stabilized, and only three patients did not respond. The responses of individual lesions in six patients were heterogeneous with regard to both the degree (ranging from cessation of growth to regression to undetectability) and the duration (ranging from less than 3 to up to 8 months). Survival times from the time of diagnosis and from the time of start of the protocol treatment ranged from 12 to 20 months and 6 to 12 months, respectively, for three patients who expired and from 10+ to 28+ months and 6+ to 12+ months, respectively, for six patients who are alive. Only one patient experienced a grade 4 toxicity (transient renal failure requiring hemodialysis). All other toxicities (grades 1-3) were easily controlled and resolved completely after 7 days. /Exptl Ther/.Growth of a human renal cancer cell line in nude mice was inhibited when the renal cancer cells were injected together with oxidizing mitogen-activated human mononuclear cells.Sodium periodate (IO4) exerts a number of biological effects including the enhancement of lymphocyte activation. In this study, /the authors/ investigated its effects on cytotoxicity of human peripheral blood lymphocytes (PBL) and explored the mechanism whereby it exerted these effects. In vitro treatment of human PBL with IO4 augmented their cytotoxicity against K562 myelogenous leukemia cells. IO4 oxidative treatment increased the frequency of effector-to-target cell binding. It also increased cellular ATP levels in effector cells, suggesting that the post-binding cytolytic functions of these cells were also enhanced after treatment with IO4. Moreover, IO4 treatment significantly increased the protein kinase C (PKC) activity of effector cells and induced the translocation of activity in the membrane fraction from the cytosol. H-7, a potent PKC inhibitor, significantly reduced this enhancement of membrane-associated PKC activity at 10 microM and significantly reduced the enhanced cytotoxicity of PBL at the same concentration. These results indicated that IO4 enhanced the binding capacity and post-binding cytolytic functions of PBL and that PKC activation was one mechanism to explain the IO4-induced cellular activation.Periodate-oxidized ADP and periodate-oxidized ATP stimulate the permeability transition in energized rat liver mitochondria measured as the Ca2+-efflux induced by Ca2+ and Pi. In the presence of Mg2+ and Pi, mitochondria lose intramitochondrial adenine nucleotides at a slow rate. Periodate-oxidized ATP induces a strong decrease of the matrix adenine nucleotides which is inhibited by carboxyatractyloside. Under these conditions, Mg2+ prevents the opening of the permeability transition pore. EGTA prevents the Pi-induced slow efflux of adenine nucleotides, but is without effect on the periodate-oxidized ATP-induced strong decrease of adenine nucleotides. This periodate oxidized ATP-induced strong adenine nucleotide efflux is inhibited by ADP. Periodate-oxidized ATP reduces the increase of matrix adenine nucleotides occurring when the mitochondria are incubated with Mg2+ and ATP. This effect of periodate-oxidized ATP is also prevented by carboxyatractyloside. Periodate-oxidized ATP is not taken up by the mitochondria. It is suggested that periodate-oxidized ATP induces a strong efflux of matrix adenine nucleotides by the interaction with the ADP/ATP carrier from the cytosolic side. The induction of the mitochondrial permeability transition by periodate-oxidized ADP and periodate-oxidized ATP is attributed to two mechanisms-a strong decrease in the intramitochondrial adenine nucleotide content, especially that of ADP, and a stabilization of the c-conformation of the ADP/ATP carrier.Source of periodic acid, analytical reagent, oxidizing agent.Tissue processing fixation: PLP fixative: 4% paraformaldehyde, 0.2% perioidate and 1.2% lysine in 0.1 M phosphate buffer.Periodate-methylamine degradation of ribonucleotides ... enables separation of deoxyribonucleotides in cell extracts by high-performance liquid chromatography.General Manufacturing Information HelpNew Window
EPA TSCA Commercial Activity Status
Periodic acid (HIO4), sodium salt (1:1): ACTIVE
Danger of Sodıum Periodate
GHS Hazard Statements
Aggregated GHS information provided by 201 companies from 18 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
H271 (39.3%): May cause fire or explosion; strong Oxidizer [Danger Oxidizing liquids; Oxidizing solids]

H272 (60.7%): May intensify fire; oxidizer [Danger Oxidizing liquids; Oxidizing solids]

H301 (23.38%): Toxic if swallowed [Danger Acute toxicity, oral]

H302 (33.83%): Harmful if swallowed [Warning Acute toxicity, oral]

H314 (38.31%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]

H315 (56.72%): Causes skin irritation [Warning Skin corrosion/irritation]

H318 (26.87%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

H319 (57.21%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

H335 (57.21%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

H372 (38.31%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]

H400 (38.31%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

 

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Human peripheral blood mononuclear cells when activated with the oxidizing mitogens, neuraminidase/galactose oxidase or sodium periodate, express cytolytic activity for freshly isolated tumor cells and for a variety of cell lines, including NK-resistant solid tumor lines. Normal lymphoid cells are not targets for cytotoxicity and do not inhibit lysis of susceptible targets mediated by the oxidizing mitogen-activated mononuclear cells. The cytotoxic response is rapidly generated and reaches peak levels at 48 hr. The oxidizing mitogens induce expression of IL 2 receptors on peripheral blood mononuclear cells. Combined treatment of cells with IL 2 and the oxidizing mitogens results in a marked enhancement of cytotoxicity. Enhancement is achieved at levels of IL 2 that alone result in minimal generation of cytotoxic cells.Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary sodium periodates. Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination .Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation .Sodium periodate stimulated lymphocytes, treated with mitomycin C, produced no growth factor activity. Partial characterization of the factor indicates that it is non-dialyzable, resistant to ribonuclease, and sensitive to heat, trypsin, and papain. lymphocytes oxidized with the mitogen sodium periodate undergo a proliferative response when cultured in the presence of Ia+ accessory cells.
Oxidation with Periodate
Sodium periodate can be used to oxidize hydroxyl groups on adjacent carbon atoms, forming reactive aldehyde residues suitable for coupling with amine- or hydrazide-containing molecules. The reaction occurs with two adjacent secondary hydroxyls to cleave the carbon-carbon bond between them and create two terminal aldehyde groups (Reaction 3.38). When one of the adjacent hydroxyls is a primary hydroxyl, reaction with periodate releases one molecule of formaldehyde and leaves a terminal aldehyde residue on the original diol compound (Reaction 3.39). These reactions can be used to generate crosslinking sites in carbohydrates or glycoproteins for subsequent conjugation of amine-containing molecules by reductive amination (Chapter 2, Section 4.4, and Chapter 4, Section 4). Sodium periodate also reacts with 2-aminoethanol derivatives-compounds containing a primary amine and a secondary hydroxyl group on adjacent carbon atoms. Oxidation cleaves the carbon-carbon bond, forming a terminal aldehyde group on the side that had the original hydroxyl residue (Reaction 3.40). This reaction can be used to create reactive aldehydes on N-terminal serine residues of peptides (Geoghegan and Stroh, 1992).Periodate Oxidation of N-Terminal Serine or Threonine Residues
Sodium periodate can be used to form aldehydes on unmodified N-terminal serine or threonine residues in proteins and peptides (Geoghegan and Stroh, 1992). Periodate cleaves carbon-carbon bonds that both possess primary or secondary hydroxyls or amines (i.e., diols or 2-amino alcohol groups). If a primary hydroxyl is present, such as in the case of N-terminal serine residues, then the reaction liberates formaldehyde and forms an aldehyde group (an α-N-glyoxylyl) at the end of the peptide (Figure 2.106). This reaction can be used to direct bioconjugation to a site-specific point on biomolecules, provided that there are no other periodate-oxidizable groups within the protein structure. A synthetic peptide designed to have an N-terminal serine or threonine residue can provide a site of coupling at the end of the chain. This strategy is a viable alternative to the incorporation of a cysteine group for bioconjugation at the end of a peptide.
Protocol for Oxidizing Dextran with Sodium Periodate
1.
Dissolve sodium periodate (NaIO4) (Sigma) in 500 ml of deionized water at a concentration of 0.03-M (6.42 g). Protect from light.
2.
Dissolve dextran (Polysciences) of molecular weight between 10,000 and 40,000 in the sodium periodate solution with stirring.Molecules containing polysaccharide chains may be oxidized to possess reactive aldehyde residues by treatment with sodium periodate.
Description
Catalogue Number 106597
Replaces SX0695-5; SX0695-5
Synonyms Sodium periodate
Product Information
CAS number 7790-28-5
EC number 232-197-6
Grade ACS,Reag. Ph Eur
Hill Formula INaO₄
Chemical formula NaIO₄
Molar Mass 213.89 g/mol
HS Code 2829 90 80
Physicochemical Information
Density 3.87 g/cm3 (20 °C)
Melting Point 270 °C decomposes
pH value 5.2 (50 g/l, H₂O, 20 °C)
Bulk density 2900 kg/m3
Solubility 91 g/l
Specifications
Assay (iodometric) ≥ 99.0 %
Assay (out of dried substance) 99.8 - 100.3 %
Identity passes test
Sulfate (SO₄) ≤ 0.005 %
other halogens (as Cl) ≤ 0.01 %
Mn (Manganese) ≤ 0.0001 %
Sodium metaperiodate
General Information About Sodium Periodate
Structure:
CAS Number: 7790-28-5

Molecular Weight: 213.89 g/mol

Appearance: White crystals

Chemical Formula: NaIO4(sodiumperiodate)

Common Uses Area of sodium periodate
Reagent in the conversion of alkenes to aldehydes (OsO4 + NaIO4)Sodium meta-Periodate
Application:A strong oxidizing hypervalent iodine compound
CAS Number:7790-28-5
Purity:≥99%
Molecular Weight:213.89
Molecular Formula:NaIO4
Supplemental Information:This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
Procedure excerpt:

The SM (1.03 g, 3.58 mmol), NaIO4 (2.34 g, 10.9 mmol), OsO4 (2.5 wt% in t-BuOH, 1.0 mL), THF (12.4 mL), and H2O (2.4 mL) were combined at RT. The reaction mixture .

Reagent for oxidizing sulfides to sulfoxides or sulfones
In a blatant plug for the Reagent Guide and the Reagents App for iPhone, each Friday I profile a different reagent that is commonly encountered in Org 1/ Org 2.
In organic chemistry, sometimes you need to build molecules up. Other times, you need to break molecules down. Ozone, which we talked about earlier, is a really useful reagent for that. Here's another one, although it's a little more obscure : Sodium periodate (NaIO4) breaks apart 1,2-diols (vicinal diols) to form aldehydes and ketones. In this respect it's the same as periodic acid (HIO4) and lead tetra-acetate [Pb(OAc)4].

Notice what's happening to NaIO4 here - it's becoming reduced from iodine(VII) to iodine(V). In the process we're cleaving a C-C bond and forming two C-O π bonds. Comes in handy sometimes, when you want to break apart an alkene and form aldehydes and ketones.
How it works Sodium Periodate

NaIO4 works by forming bonds with alcohols to the iodine. In the second step, what happens is a kind of reverse cycloaddition (similar to what happens when an ozonide breaks down). This is a somewhat simplified version of the mechanism (skipping over the proton transfer). The key part here is the third diagram, where the cyclic iodate ester breaks down to give the ketone and aldehyde.

And there you go: aldehydes or ketones, depending on whether you're breaking down secondary or tertiary alcohols (primary alcohols become formaldehyde). So this actually gives you a second way to cleave double bonds to alkenes/ketones besides ozone. You can take an alkene, treat it with osmium tetroxide (OsO4) first to make the diol, and then NaIO4 it. This is, incidentally, sometimes called "Johnson-Lemieux cleavage". Obscure organic chemistry named reaction of the day!
VARIO Sodyum periyodat F10 Kolay ve hızlı sunum şekli, bu toz ayıraçlarını birçok ülkede, su analizi için popüler ayıraçlar haline getirmektedir.
Lovibond® toz ayıraçları yelpazesi, bilinen kullanıcılara mevcut ölçüm sistemleri için bir alternatif sunar.
Toz ayıraçları, Tintometer GmbH, Lovibond® Water Testing'i ayıraç tabletleri alanındaki on yıllardır başarısını borçlu olduğu aynı nitel gerekliliklerle üretilir.
Alüminyumdan klora ve sülfata kadar değişen parametreler, toz ayıraçları yelpazesi ile karşılanabilen, dünya çapında bilinen parametrelerdir.

Acar Kimya A.Ş. © 2015 Tüm Hakları Saklıdır.